QQ客服 官方微博 反馈留言

	A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects
	Zhang, Tan; Chen, Guihong; Liu, Chang; Zu, Li'an; Wang, Qi; Wang, Yitong; Lv, Jie; An, Youzhong; Dong, Lihou; Cheng, Huiyang
刊名	BIODRUGS
	2019
卷号	33期号:1
ISSN号	1173-8804
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3629585
专题	上海中医药大学
推荐引用方式 GB/T 7714	Zhang, Tan,Chen, Guihong,Liu, Chang,et al. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects[J]. BIODRUGS,2019,33(1).
APA	Zhang, Tan.,Chen, Guihong.,Liu, Chang.,Zu, Li'an.,Wang, Qi.,...&Fang, Yi.(2019).A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects.BIODRUGS,33(1).
MLA	Zhang, Tan,et al."A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects".BIODRUGS 33.1(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。